secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2024-09-23T23:59:59+00:00
Accession:  0001193125-24-223726
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia CEO Stephen R. Davis terminated Sept 23; Catherine Owen Adams appointed
------------------------------------------------------------------------------

- Stephen R. Davis involuntarily terminated without cause as President and CEO effective Sept 23, 2024; resigns from board.
- Davis receives severance: 1.5x base+target bonus, pro-rata 2024 bonus, 12 months accelerated equity, 18 months COBRA.
- Catherine Owen Adams appointed CEO and director effective Sept 23; previously SVP and GM U.S. at BMS overseeing $20B business.
- Adams compensation: $900k base salary, 80% target bonus, $500k sign-on, plus equity awards of $3.25M in options and $3.25M in PSUs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000119312524223726/0001193125-24-223726-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000119312524223726/d861822d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-223726

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer